source
- US biotech M&A surges as Chinese licensing deals dominate 2026 marketLocust Walk reports that China now accounts for 58% of global licensing deal value in 2026, while the United States share has dropped to 26%. Despite the licensing shift, US biotech companies are…
- Disc Medicine’s Phase 3 data revives rejected rare‑disease drug as China tightens biotech ownership rulesDisc Medicine announced that its Phase 3 trial of a previously rejected rare‑disease therapy showed positive results, effectively rescuing the program and positioning it for another submission to t…